- Home
- Publications
- Publication Search
- Publication Details
Title
Angiogenesis as a hallmark of solid tumors - clinical perspectives
Authors
Keywords
-
Journal
CELLULAR ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-04-09
DOI
10.1007/s13402-021-00602-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer
- (2021) Keywan Mortezaee JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
- Steps in metastasis: an updated review
- (2021) Jamal Majidpoor et al. MEDICAL ONCOLOGY
- Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance
- (2021) Hassan Yousefi et al. ONCOGENE
- Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial
- (2021) Sandro Pignata et al. LANCET ONCOLOGY
- Organ tropism in solid tumor metastasis: an updated review
- (2021) Keywan Mortezaee Future Oncology
- Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group
- (2020) T. André et al. ANNALS OF ONCOLOGY
- First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design
- (2020) Thierry André et al. Future Oncology
- Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003
- (2020) Arkadiusz Z. Dudek et al. JOURNAL OF CLINICAL ONCOLOGY
- Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future
- (2020) Eric S Christenson et al. LANCET ONCOLOGY
- Checkpoint inhibitor immunotherapy in kidney cancer
- (2020) Wenxin Xu et al. Nature Reviews Urology
- The Interplay of the Extracellular Matrix and Stromal Cells as a Drug Target in Stroma-Rich Cancers
- (2020) Nina Kozlova et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
- (2020) T.K. Choueiri et al. ANNALS OF ONCOLOGY
- Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
- (2020) Xinan Sheng et al. BMC CANCER
- IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation
- (2020) Stephen P Hack et al. Future Oncology
- A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma
- (2020) L.R. Duska et al. GYNECOLOGIC ONCOLOGY
- Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
- (2020) Jacobus Pfisterer et al. LANCET ONCOLOGY
- CXCL12/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis
- (2020) Keywan Mortezaee LIFE SCIENCES
- Pancreatic cancer stroma: an update on therapeutic targeting strategies
- (2020) Abdel N. Hosein et al. Nature Reviews Gastroenterology & Hepatology
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer
- (2020) Masaaki Miyo et al. BMC CANCER
- AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
- (2020) Carlotta Antoniotti et al. BMC CANCER
- Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
- (2020) Michael S Lee et al. LANCET ONCOLOGY
- First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study
- (2020) Shousheng Liu et al. Scientific Reports
- A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI)
- (2020) Katsunori Shinozaki et al. International Journal of Clinical Oncology
- Pembrolizumab plus axitinib: another step ahead in advanced renal cell carcinoma
- (2020) Giuseppe Procopio et al. LANCET ONCOLOGY
- Immune escape: A critical hallmark in solid tumors
- (2020) Keywan Mortezaee LIFE SCIENCES
- Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
- (2020) Robert J. Motzer et al. NATURE MEDICINE
- Management of brain metastases according to molecular subtypes
- (2020) Riccardo Soffietti et al. Nature Reviews Neurology
- Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer
- (2020) Benoist Chibaudel et al. JAMA Network Open
- Redox tolerance and metabolic reprogramming in solid tumors
- (2020) Keywan Mortezaee CELL BIOLOGY INTERNATIONAL
- Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives
- (2020) Keywan Mortezaee et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Perivascular cell-specific knockout of the stem cell pluripotency gene Oct4 inhibits angiogenesis
- (2019) Daniel L. Hess et al. Nature Communications
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The adjuvant treatment of kidney cancer: a multidisciplinary outlook
- (2019) Camillo Porta et al. Nature Reviews Nephrology
- Vessel co-option in cancer
- (2019) Elizabeth A. Kuczynski et al. Nature Reviews Clinical Oncology
- Regulation of tumor angiogenesis and mesenchymal–endothelial transition by p38α through TGF-β and JNK signaling
- (2019) Raquel Batlle et al. Nature Communications
- Rational combinations of immunotherapy with radiotherapy in ovarian cancer
- (2019) Fernanda G Herrera et al. LANCET ONCOLOGY
- Cancer stem cell (a)symmetry & plasticity: Tumorigenesis and therapy relevance
- (2019) Masoud Najafi et al. LIFE SCIENCES
- Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Post Hoc Analysis of the VELOUR Trial
- (2019) Eric Van Cutsem et al. CLINICAL CANCER RESEARCH
- Resveratrol as an adjuvant for normal tissues protection and tumor sensitization
- (2019) Keywan Mortezaee et al. CURRENT CANCER DRUG TARGETS
- Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer
- (2019) Sarah E. Taylor et al. GYNECOLOGIC ONCOLOGY
- Hypoxia in solid tumors: a key promoter of cancer stem cell (CSC) resistance
- (2019) Masoud Najafi et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features
- (2019) Bradley A. McGregor et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- (2019) Robert J Motzer et al. LANCET ONCOLOGY
- Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies
- (2019) Yun-Chieh Sung et al. Nature Nanotechnology
- Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities
- (2019) Anna Brodziak et al. Nature Reviews Urology
- Hypoxia induces core-to-edge transition of progressive tumoral cells: A critical review on differential yet corroborative roles for HIF-1α and HIF-2α
- (2019) Keywan Mortezaee LIFE SCIENCES
- Stromal reprogramming: A target for tumor therapy
- (2019) Masoud Najafi et al. LIFE SCIENCES
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- (2019) Isabelle Ray-Coquard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting glioblastoma-derived pericytes improves chemotherapeutic outcome
- (2018) Daniel A. P. Guerra et al. ANGIOGENESIS
- Contribution of Tumor Endothelial Cells in Cancer Progression
- (2018) Kyoko Hida et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Extracellular vesicles in cancer — implications for future improvements in cancer care
- (2018) Rong Xu et al. Nature Reviews Clinical Oncology
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- Cancer Associated Fibroblasts: The Architects of Stroma Remodeling
- (2018) Alice Santi et al. PROTEOMICS
- Cancer-associated fibroblasts: Secretions, interactions, and therapy
- (2018) Bagher Farhood et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- The hallmarks of successful anticancer immunotherapy
- (2018) Lorenzo Galluzzi et al. Science Translational Medicine
- The obese adipose tissue microenvironment in cancer development and progression
- (2018) Daniela F. Quail et al. Nature Reviews Endocrinology
- Tissue necrosis and its role in cancer progression
- (2018) Adi Karsch-Bluman et al. ONCOGENE
- NADPH oxidase as a target for modulation of radiation response; implications to carcinogenesis and radiotherapy
- (2018) Keywan Mortezaee et al. Current Molecular Pharmacology
- Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses
- (2017) Carlos Bais et al. JNCI-Journal of the National Cancer Institute
- Erratum to: Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p
- (2017) Wei Lu et al. Molecular Cancer
- Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
- (2017) Lin Tian et al. NATURE
- Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1
- (2017) Y-L Hsu et al. ONCOGENE
- Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses
- (2017) Carlos Bais et al. JNCI-Journal of the National Cancer Institute
- In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab
- (2016) Shigeto Ueda et al. BRITISH JOURNAL OF CANCER
- Progression and metastasis of lung cancer
- (2016) Helmut H. Popper CANCER AND METASTASIS REVIEWS
- Vascular mimicry formation is promoted by paracrine TGF-β and SDF1 of cancer-associated fibroblasts and inhibited by miR-101 in hepatocellular carcinoma
- (2016) Jine Yang et al. CANCER LETTERS
- Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma
- (2016) Jayashree Kalpathy-Cramer et al. JOURNAL OF NEURO-ONCOLOGY
- Ultrasound Triggered Tumor Oxygenation with Oxygen-Shuttle Nanoperfluorocarbon to Overcome Hypoxia-Associated Resistance in Cancer Therapies
- (2016) Xuejiao Song et al. NANO LETTERS
- Early pancreatic cancer lesions suppress pain through CXCL12-mediated chemoattraction of Schwann cells
- (2016) Ihsan Ekin Demir et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pericyte–fibroblast transition promotes tumor growth and metastasis
- (2016) Kayoko Hosaka et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Heat Shock Proteins Promote Cancer: It's a Protection Racket
- (2016) Stuart K. Calderwood et al. TRENDS IN BIOCHEMICAL SCIENCES
- Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
- (2016) Yu-Ling Li et al. Cancer Biology & Medicine
- Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine
- (2015) Giuseppe Curigliano et al. BREAST
- A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma
- (2015) Brian I. Rini et al. JOURNAL OF UROLOGY
- A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma
- (2015) Elizabeth R. Gerstner et al. NEURO-ONCOLOGY
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Tumor Vessel Normalization by Chloroquine Independent of Autophagy
- (2014) Hannelore Maes et al. CANCER CELL
- An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer
- (2014) M. S. Gordon et al. CLINICAL CANCER RESEARCH
- Three-Dimensional Contrast-Enhanced Sonography in the Assessment of Breast Tumor Angiogenesis
- (2014) Man Chen et al. JOURNAL OF ULTRASOUND IN MEDICINE
- When Cancer Co-opts the Vasculature
- (2014) Francesco Pezzella et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer
- (2014) N B Volz et al. PHARMACOGENOMICS JOURNAL
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts
- (2014) Suling Liu et al. Stem Cell Reports
- MicroRNAs and Tumor Vasculature Normalization: Impact on Anti-Tumor Immune Response
- (2013) Agata Matejuk et al. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
- Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy
- (2013) Felix Klug et al. CANCER CELL
- Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab
- (2013) Matthew D. Hellmann et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Glioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth
- (2013) Lin Cheng et al. CELL
- Dynamic Contrast-Enhanced MR Imaging in a Phase Ⅱ Study on Neoadjuvant Chemotherapy Combining Rh-Endostatin with Docetaxel and Epirubicin for Locally Advanced Breast Cancer
- (2013) Qianxin Jia et al. International Journal of Medical Sciences
- Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
- (2013) Jonathan Welti et al. JOURNAL OF CLINICAL INVESTIGATION
- Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy
- (2013) Kyrre E Emblem et al. NATURE MEDICINE
- Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
- (2013) T. T. Batchelor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combining two strategies to improve perfusion and drug delivery in solid tumors
- (2013) T. Stylianopoulos et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumour angiogenesis regulation by the miR-200 family
- (2013) Chad V. Pecot et al. Nature Communications
- A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer
- (2012) Giampietro Gasparini et al. ANGIOGENESIS
- A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors
- (2012) J. R. Strosberg et al. ANNALS OF ONCOLOGY
- VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
- (2012) N G Gavalas et al. BRITISH JOURNAL OF CANCER
- Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway
- (2012) Vesselina G. Cooke et al. CANCER CELL
- Hypoxia-Induced Autophagy Promotes Tumor Cell Survival and Adaptation to Antiangiogenic Treatment in Glioblastoma
- (2012) Y.-L. Hu et al. CANCER RESEARCH
- Changes in Tumor Blood Flow as Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) May Predict Activity of Single Agent Bevacizumab in Recurrent Epithelial Ovarian (EOC) and Primary Peritoneal Cancer (PPC) Patients: An exploratory analysis of a Gynecologic Oncology Group Phase II study
- (2012) Dana M. Chase et al. GYNECOLOGIC ONCOLOGY
- Can Determination of Circulating Endothelial Cells and Serum Caspase-Cleaved CK18 Predict for Response and Survival in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Endostatin and Paclitaxel–Carboplatin Chemotherapy? A Retrospective Study
- (2012) Tian-Qing Chu et al. Journal of Thoracic Oncology
- Cancer prevention by targeting angiogenesis
- (2012) Adriana Albini et al. Nature Reviews Clinical Oncology
- Tumor Cell Plasticity and Angiogenesis in Human Melanomas
- (2012) Daniela Mihic-Probst et al. PLoS One
- Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
- (2012) S. J. Conley et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hypoxia control to normalize pathologic angiogenesis: Potential role for endothelial precursor cells and miRNAs regulation
- (2012) Guillaume Collet et al. VASCULAR PHARMACOLOGY
- Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
- (2012) Melissa Taylor et al. Cancer Discovery
- HRG Inhibits Tumor Growth and Metastasis by Inducing Macrophage Polarization and Vessel Normalization through Downregulation of PlGF
- (2011) Charlotte Rolny et al. CANCER CELL
- Basic and Therapeutic Aspects of Angiogenesis
- (2011) Michael Potente et al. CELL
- Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics
- (2011) T. Yau et al. CLINICAL CANCER RESEARCH
- VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2
- (2011) Apostolos C. Ziogas et al. INTERNATIONAL JOURNAL OF CANCER
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- Antiangiogenic therapy, hypoxia and metastasis: risky liaisons, or not?
- (2011) Katrien De Bock et al. Nature Reviews Clinical Oncology
- Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
- (2011) Peter Carmeliet et al. NATURE REVIEWS DRUG DISCOVERY
- Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
- (2011) J. F. de Groot et al. NEURO-ONCOLOGY
- Normalization of the Vasculature for Treatment of Cancer and Other Diseases
- (2011) Shom Goel et al. PHYSIOLOGICAL REVIEWS
- Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib
- (2011) Romain Coriat et al. PLoS One
- Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
- (2011) Olivier Keunen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- VEGF and angiopoietin signaling in tumor angiogenesis and metastasis
- (2011) Pipsa Saharinen et al. TRENDS IN MOLECULAR MEDICINE
- Delivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies
- (2011) Vikash P. Chauhan et al. Annual Review of Chemical and Biomolecular Engineering
- Bevacizumab improves the delivery and efficacy of paclitaxel
- (2010) Mieko Yanagisawa et al. ANTI-CANCER DRUGS
- In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer
- (2010) Martin Pölcher et al. BMC CANCER
- Tumors as Organs: Complex Tissues that Interface with the Entire Organism
- (2010) Mikala Egeblad et al. DEVELOPMENTAL CELL
- 18F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer
- (2010) Ashley M. Groves et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer
- (2010) Ernest S. Han et al. GYNECOLOGIC ONCOLOGY
- Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma
- (2010) John A. Boockvar et al. JOURNAL OF NEUROSURGERY
- Effect of Pazopanib on Tumor Microenvironment and Liposome Delivery
- (2010) T. D. Tailor et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms of Vessel Branching
- (2009) Frederik De Smet et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab
- (2009) Mitsukuni Suenaga et al. MEDICAL ONCOLOGY
- Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization
- (2008) A. Claes et al. MOLECULAR CANCER THERAPEUTICS
- Vascular normalization in Rgs5-deficient tumours promotes immune destruction
- (2008) Juliana Hamzah et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now